Baricitinib, an oral reversible Janus kinase 1 and 2 inhibitor, for atopic dermatitis: Head and neck response across two phase 3 studies - Simpson, Eric; Bissonnette, Robert; Nunes, Fabio P.; Rueda, Maria Jose; Paul, Carle (JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020)